Clinical Trial: MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Phase II Trial of MGCD516, a Multi-receptor Tyrosine Kinase Inhibitor, in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Brief Summary:
Primary Objective:
- To assess the efficacy of MGCD516 in patients with advanced liposarcoma by evaluating the progression free rate at 12 weeks as compared historical controls.
Secondary Objectives:
- To further evaluate the safety profile of MGCD516 by assessing adverse event rates (according to National Cancer Institute CTCAE version 4.0 criteria) in patients treated with this agent.
- To assess the efficacy of MGCD516 in patients with advanced liposarcoma by evaluating the overall response rate (according to RECIST 1.1 criteria), progression free survival and overall survival in patients treated with this agent.
